Search Within

Yelena Yuriy Janjigian

Formats
  1. Meeting Abstract (217)
  2. Journal Article (156)
  3. Review (11)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (400)
  2. Gastrointestinal Oncology Service (400)
  3. Solid Tumor Oncology Division (400)
  4. Center for Pancreatic Cancer Research (161)
  5. Surgery (148)
  6. Department of Pathology and Laboratory Medicine (137)

More Groups

People
  1. David Ilson (112)
  2. Geoffrey Ku (110)
  3. Laura Tang (84)
  4. David Kelsen (74)
  5. Steven Maron (65)
  6. Vivian Strong (65)

More People

Years
  1. 2025 (20)
  2. 2024 (33)
  3. 2023 (42)
  4. 2022 (37)
  5. 2021 (54)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (146)
  2. Annals of Oncology (44)
  3. Annals of Surgical Oncology (14)
  4. Annals of Surgery (13)
  5. Clinical Cancer Research (13)
  6. Oncology Research and Treatment (11)

More Publications

Publishers
  1. American Society of Clinical Oncology (152)
  2. Oxford University Press (51)
  3. American Association for Cancer Research (28)
  4. Springer (22)
  5. Elsevier Inc. (19)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (400)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Differences in ancestry and presence of gastric precursor lesions in individuals with young- and average-onset gastric cancer
    Journal Article

    Magahis, P. T.; Cornet, N.; Tang, L.; Arora, K.; Hingorani, N.; King, S.; Markowitz, A. J.; Schattner, M.; Shimada, S.; Maron, S. B.; more...
    Cancer Medicine (2024)

    Fulltext@MSK | Save
  • EGFR-directed antibodies promote HER2 ADC internalization and efficacy
    Journal Article

    Gupta, A.; Michelini, F.; Shao, H.; Yeh, C.; Drago, J. Z.; Liu, D.; Rosiek, E.; Romin, Y.; Ghafourian, N.; Thyparambil, S.; more...
    Cell Reports Medicine (2024)

    Fulltext@MSK | Save
  • Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)
    Meeting Abstract

    Janjigian, Y. Y.; Raoufmoghaddam, S.; Sztachelska, M.; Winter, M.; Das, S.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS
    Meeting Abstract

    Cytryn, S. L.; Phu, W.; Shah, R. H.; Walch, H. S.; Chatila, W. K.; Vakiani, E.; Brannon, A. R.; Ladanyi, M.; Srivastava, A.; Tang, L. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using (18)F-BMS-986229 PET
    Meeting Abstract

    Cytryn, S. L.; Pandit-Taskar, N.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Feder, L.; Philemond, S.; Lyashchenko, S. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649
    Meeting Abstract

    Shitara, K.; Moehler, M. H.; Ajani, J. A.; Shen, L.; Garrido, M.; Gallardo, C.; Wyrwicz, L. S.; Yamaguchi, K.; Cleary, J. M.; Elimova, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Wu, A. J. C.; Trivedi, N.; Maron, S. B.; Joshi, S. S.; Ilson, D. H.; Janjigian, Y. Y.; Shcherba, M.; Li, J.; Tang, L. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • BRAF variants and oncogenic fusions to define sporadic MMR-deficient colorectal cancer subtypes
    Meeting Abstract

    Abdelfattah, S.; Harada, G.; Patel, S.; Artz, O.; Yaeger, R.; Johannet, P.; Harrold, E.; Walch, H. S.; Argiles, G.; Rousseau, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
    Meeting Abstract

    Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Oh, D. Y.; Omori, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results
    Meeting Abstract

    Janjigian, Y. Y.; Kawazoe, A.; Xu, J.; Lonardi, S.; Metges, J. P.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y.; Bilici, M.; Lowery, M. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save